Sign in
CompletedNo phase

The Cre8™ BTK Post Market Clinical Follow-up Study

Key facts

Who runs it
CID S.p.A.
Where
Italy2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
12 Apr 2023
Ended
31 Jan 2024
Type of study
Observational
Treatments tested
  • Cre8™ BTK
Record updated
22 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (3)Hide the full registry criteria

Who can take part

  • Patient has been implanted with at least one Cre8™ BTK device according to the indications described in the Instructions for Use (IFU),
  • Study device implantation date is at least one year (12 months) prior to the starting date of the retrospective anonymous data collection

Who cannot take part

  • Patients treated less than 12 months prior to study start

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cre8™ BTK is a CE marked drug eluting stent, integrally coated with i-Carbofilm, loaded with formulated Sirolimus for the treatment of infrapopliteal peripheral artery disease.

Read full original descriptionShow less

The aim of this post-market retrospective study protocol P32102 is to collect clinical data of patient treated with Cre8™ BTK stent in routine clinical practice.

In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the Cre8™ BTK stent at least 12 months prior to the study start.

Treatments tested

  • Cre8™ BTK

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sirolimus Drug-eluting Stent for the Treatment of Infrapopliteal Peripheral Artery Disease: Evaluation of Safety and Performance in Everyday Clinical Practice. The Cre8™ BTK Post Market Clinical Follow-up Study.
Record updated
22 October 2026